2 results match your criteria: "The Affiliated Beijing Luhe Hospital of Capital Medical University[Affiliation]"
All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP.
Blood
January 2022
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
The study aimed to compare the efficacy and safety of all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy in corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients. Recruited patients were randomized at a ratio of 2:1 into 2 groups: 112 patients received LD-RTX plus ATRA, and 56 patients received LD-RTX monotherapy. Overall response (OR), defined as achieving a platelet count of ≥30 × 109/L confirmed on ≥2 separate occasions (≥7 days apart), at least a doubling of the baseline platelet count without any other ITP-specific treatment, and the absence of bleeding within 1 year after enrollment, was observed in more patients in the LD-RTX plus ATRA group (80%) than in the LD-RTX monotherapy group (59%) (between-group difference, 0.
View Article and Find Full Text PDFImmune prognostic risk score model in acute myeloid leukemia with normal karyotype.
Oncol Lett
December 2020
Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China.
Article Synopsis
- Acute myeloid leukemia with normal karyotype (NK-AML) shows high variability, and immune processes play a crucial role in its development.
- A study examined immune-related gene expression in 60 NK-AML patients from The Cancer Genome Atlas and 104 from the GEO dataset, identifying a significant association between 42 and 203 immune-related genes and overall survival.
- A risk model based on nine key immune-related genes enables the stratification of NK-AML patients into high- and low-risk groups, with a predictive accuracy of 0.793, highlighting the potential for improved prognosis through immunogenomic evaluation.